Symbols / PCSA
PCSA Chart
About
Processa Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, develops chemotherapy drugs to improve the safety and efficacy of cancer treatment. Its drugs are modifications of existing FDA-approved oncology drugs resulting in an alteration of the metabolism and/or distribution of drugs while maintaining the existing mechanisms of killing the cancer cells. The company's pipeline includes three chemotherapy drugs comprising Gemcitabine, PCS3117 that has completed Phase 2a clinical trials to treat pancreatic, biliary tract, lung, ovarian, breast, and other cancers; Capecitabine, a combination of PCS6422 and capecitabine, which is in Phase 2 clinical trials to treat metastatic colorectal, gastrointestinal, breast, pancreatic, and other cancers; and Irinotecan, PCS11T that is in pre-clinical studies to treat lung, colorectal, gastrointestinal, pancreatic, and other cancers. It also develops non-oncology drugs consisting of PCS12852 that is in Phase 2B clinical trials for treatment of gastroparesis; and PCS499 for the treatment of glomerular disease. The company has license agreements with Elion Oncology, Inc.; Ocuphire Pharma, Inc.; Aposense, Ltd.; Yuhan Corporation; and CoNCERT Pharmaceuticals, Inc. Processa Pharmaceuticals, Inc. was founded in 2017 and is based in Hanover, Maryland.
Fundamentals
Scroll to Statements| Sector | Healthcare | Industry | Biotechnology | Market Cap | 4.40M |
| Enterprise Value | -1.91M | Income | -12.93M | Sales | — |
| Book/sh | 2.76 | Cash/sh | 2.78 | Dividend Yield | — |
| Payout | 0.00% | Employees | 10 | IPO | — |
| P/E | — | Forward P/E | -0.52 | PEG | — |
| P/S | — | P/B | 0.70 | P/C | — |
| EV/EBITDA | 0.15 | EV/Sales | — | Quick Ratio | 3.61 |
| Current Ratio | 3.76 | Debt/Eq | — | LT Debt/Eq | — |
| EPS (ttm) | -28.75 | EPS next Y | -3.75 | EPS Growth | — |
| Revenue Growth | — | Earnings | 2025-11-06 16:00 | ROA | -129.94% |
| ROE | -270.74% | ROIC | — | Gross Margin | 0.00% |
| Oper. Margin | 0.00% | Profit Margin | 0.00% | Shs Outstand | 2.27M |
| Shs Float | 2.04M | Short Float | 1.34% | Short Ratio | 0.32 |
| Short Interest | — | 52W High | 19.62 | 52W Low | 1.84 |
| Beta | 1.02 | Avg Volume | 812.51K | Volume | 29.26K |
| Target Price | $25.00 | Recom | None | Prev Close | $1.85 |
| Price | $1.94 | Change | 4.86% |
Valuation Models
Price estimates from analyst targets and simple models.
1. Analyst consensus
$25.00
Mean price target
2. Current target
$1.94
Latest analyst target
3. DCF / Fair value
$-39.35
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$1.94
Low
$25.00
High
$25.00
Mean
$25.00
Latest analyst rating changes
| Date | Action | Analyst | Rating Change | Price Target |
|---|---|---|---|---|
| 2025-09-02 | main | HC Wainwright & Co. | Buy → Buy | $1 |
| 2025-06-30 | main | HC Wainwright & Co. | Buy → Buy | $2 |
| 2024-12-05 | reit | HC Wainwright & Co. | Buy → Buy | $6 |
| 2024-08-20 | reit | HC Wainwright & Co. | Buy → Buy | $6 |
| 2024-08-19 | main | HC Wainwright & Co. | Buy → Buy | $6 |
| 2024-08-01 | reit | HC Wainwright & Co. | Buy → Buy | $8 |
| 2024-06-12 | reit | HC Wainwright & Co. | Buy → Buy | $8 |
| 2024-05-13 | reit | HC Wainwright & Co. | Buy → Buy | $8 |
| 2024-04-25 | init | HC Wainwright & Co. | — → Buy | $8 |
| 2024-03-06 | reit | Benchmark | Speculative Buy → Speculative Buy | $4 |
- Will Processa Pharmaceuticals (NASDAQ:PCSA) Spend Its Cash Wisely? - Yahoo Finance Wed, 17 Dec 2025 08
- Early breast cancer trial tests drug mix for more impact, similar side effects - Stock Titan Wed, 17 Dec 2025 08
- Processa Pharmaceuticals stock soars after cancer drug shows promising results - Investing.com Wed, 17 Dec 2025 08
- Alliance Entertainment and Processa Pharmaceuticals Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV - Florida Today hu, 29 Jan 2026 12
- Why did Processa Pharmaceuticals stock surge 160% today? - MSN Wed, 17 Dec 2025 08
- $PCSA stock is up 19% today. Here's what we see in our data. - Nasdaq Wed, 09 Jul 2025 07
- Processa Pharmaceuticals (PCSA) Stock: Phase 2 Breast Cancer Update, 1-for-25 Reverse Split, and What Wall Street Is Watching on Dec. 18, 2025 - TechStock² hu, 18 Dec 2025 08
- Here’s Why Penny Stock Processa Pharmaceuticals (PCSA) Is Exploding Today - TipRanks Wed, 17 Dec 2025 08
- Processa Pharmaceuticals Reports Promising Preliminary Phase 2 Data for NGC-Cap Combination Therapy in Advanced Breast Cancer - Quiver Quantitative Wed, 17 Dec 2025 08
- Why Did Processa Pharmaceuticals Stock Surge 160% Today? - Stocktwits Wed, 17 Dec 2025 08
- Biotech Pioneer Processa Pharmaceuticals Embraces Crypto: Strategic Investment Meets Blockchain Innovation - Stock Titan hu, 07 Aug 2025 07
- PCSA Stock Soars on Upbeat Clinical Update From Breast Cancer Study - Yahoo Finance hu, 18 Dec 2025 08
- Biotech Stocks Surge After Hours: PCSA, PALI, And QTTB Lead On Volume And Speculation - Nasdaq Wed, 08 Oct 2025 07
- Processa Pharmaceuticals announces 1-for-25 reverse stock split effective this week - Investing.com Mon, 15 Dec 2025 08
- Processa Ends PCS12852 Licensing Pact With Intact Therapeutics - TipRanks hu, 19 Feb 2026 21
Insider Transactions
| Date | Shares | Url | Text | Insider | Position | Transaction | Start Date | Ownership | Value |
|---|---|---|---|---|---|---|---|---|---|
| 0 | 193 | — | — | LIN PATRICK | Officer | — | 2025-12-31 00:00:00 | D | nan |
| 1 | 249 | — | — | BIGORA SIAN | Officer | — | 2025-12-31 00:00:00 | D | nan |
| 2 | 193 | — | — | GUY WENDY | Officer | — | 2025-12-31 00:00:00 | D | nan |
| 3 | 49 | — | — | YOUNG DAVID | Officer and Director | — | 2025-12-31 00:00:00 | D | nan |
| 4 | 14482 | — | — | LIN PATRICK | Officer | — | 2025-04-01 00:00:00 | D | nan |
| 5 | 15059 | — | — | BIGORA SIAN | Officer | — | 2025-04-01 00:00:00 | D | nan |
| 6 | 14482 | — | — | GUY WENDY | Officer | — | 2025-04-01 00:00:00 | D | nan |
| 7 | 17272 | — | — | YOUNG DAVID | Officer and Director | — | 2025-04-01 00:00:00 | D | nan |
| 8 | 43500 | — | Purchase at price 0.80 per share. | LIN PATRICK | Officer | — | 2025-01-27 00:00:00 | I | 34691.0 |
| 9 | 12400 | — | Purchase at price 0.80 per share. | YORKE JUSTIN W | Director | — | 2025-01-27 00:00:00 | I | 9889.0 |
Financials
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| TaxEffectOfUnusualItems | 0.00 | 0.00 | 0.00 | -17.88K |
| TaxRateForCalcs | 0.00 | 0.00 | 0.00 | 0.04 |
| NormalizedEBITDA | -12.05M | -11.46M | -12.20M | -10.37M |
| TotalUnusualItems | 0.00 | -7.27M | -402.81K | |
| TotalUnusualItemsExcludingGoodwill | 0.00 | -7.27M | -402.81K | |
| NetIncomeFromContinuingOperationNetMinorityInterest | -11.85M | -11.12M | -27.42M | -11.43M |
| ReconciledDepreciation | 782.00 | 222.00 | 788.50K | 790.97K |
| EBITDA | -12.05M | -11.46M | -19.47M | -10.78M |
| EBIT | -12.05M | -11.46M | -20.26M | -11.57M |
| NetInterestIncome | 201.09K | 335.54K | 101.20K | 11.63K |
| InterestExpense | 362.00 | |||
| InterestIncome | 201.09K | 335.54K | 101.20K | 11.63K |
| NormalizedIncome | -11.85M | -11.12M | -20.16M | -11.04M |
| NetIncomeFromContinuingAndDiscontinuedOperation | -11.85M | -11.12M | -27.42M | -11.43M |
| TotalExpenses | 12.05M | 11.46M | 20.26M | 11.57M |
| TotalOperatingIncomeAsReported | -12.05M | -11.46M | -27.53M | -12.13M |
| DilutedAverageShares | 122.40K | 52.46K | 32.22K | 30.64K |
| BasicAverageShares | 122.40K | 52.46K | 32.22K | 30.64K |
| DilutedEPS | -96.75 | -212.00 | -851.25 | -375.00 |
| BasicEPS | -96.75 | -212.00 | -851.25 | -375.00 |
| DilutedNIAvailtoComStockholders | -11.85M | -11.12M | -27.42M | -11.43M |
| NetIncomeCommonStockholders | -11.85M | -11.12M | -27.42M | -11.43M |
| OtherunderPreferredStockDividend | 0.00 | |||
| NetIncome | -11.85M | -11.12M | -27.42M | -11.43M |
| NetIncomeIncludingNoncontrollingInterests | -11.85M | -11.12M | -27.42M | -11.43M |
| NetIncomeContinuousOperations | -11.85M | -11.12M | -27.42M | -11.43M |
| TaxProvision | 0.00 | 0.00 | -530.61K | |
| PretaxIncome | -11.85M | -11.12M | -27.42M | -11.96M |
| OtherIncomeExpense | -7.27M | -402.81K | ||
| SpecialIncomeCharges | 0.00 | -7.27M | -402.81K | |
| OtherSpecialCharges | 402.81K | |||
| ImpairmentOfCapitalAssets | 0.00 | 7.27M | 0.00 | |
| NetNonOperatingInterestIncomeExpense | 201.09K | 335.54K | 101.20K | 11.63K |
| InterestExpenseNonOperating | 362.00 | |||
| InterestIncomeNonOperating | 201.09K | 335.54K | 101.20K | 11.63K |
| OperatingIncome | -12.05M | -11.46M | -20.26M | -11.57M |
| OperatingExpense | 12.05M | 11.46M | 20.26M | 11.57M |
| ResearchAndDevelopment | 7.27M | 5.80M | 11.49M | 6.88M |
| SellingGeneralAndAdministration | 4.78M | 5.66M | 8.76M | 4.69M |
| GeneralAndAdministrativeExpense | 4.78M | 5.66M | 8.76M | 4.69M |
| OtherGandA | 4.78M | 5.66M | 8.76M | 4.69M |
| TotalRevenue | 0.00 | 0.00 | 0.00 | 0.00 |
| OperatingRevenue | 0.00 | 0.00 | 0.00 | 0.00 |
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | |
|---|---|---|---|---|
| TreasurySharesNumber | 200.00 | 200.00 | 200.00 | |
| OrdinarySharesNumber | 148.10K | 51.44K | 32.07K | 31.42K |
| ShareIssued | 148.31K | 51.64K | 32.27K | 31.42K |
| TotalDebt | 73.51K | 150.55K | 229.45K | 78.46K |
| TangibleBookValue | 1.70M | 4.99M | 7.47M | 17.43M |
| InvestedCapital | 1.70M | 4.99M | 7.47M | 25.49M |
| WorkingCapital | 340.99K | 4.90M | 7.39M | 17.36M |
| NetTangibleAssets | 1.70M | 4.99M | 7.47M | 17.43M |
| CapitalLeaseObligations | 73.51K | 150.55K | 229.45K | 78.46K |
| CommonStockEquity | 1.70M | 4.99M | 7.47M | 25.49M |
| TotalCapitalization | 1.70M | 4.99M | 7.47M | 25.49M |
| TotalEquityGrossMinorityInterest | 1.70M | 4.99M | 7.47M | 25.49M |
| StockholdersEquity | 1.70M | 4.99M | 7.47M | 25.49M |
| TreasuryStock | 300.00K | 300.00K | 300.00K | 0.00 |
| RetainedEarnings | -87.22M | -75.37M | -64.25M | -36.82M |
| AdditionalPaidInCapital | 89.21M | 80.66M | 72.02M | 62.31M |
| CapitalStock | 371.00 | 129.00 | 80.00 | 1.57K |
| CommonStock | 371.00 | 129.00 | 80.00 | 1.57K |
| TotalLiabilitiesNetMinorityInterest | 1.53M | 797.48K | 1.15M | 978.40K |
| TotalNonCurrentLiabilitiesNetMinorityInterest | 487.00 | 66.91K | 150.55K | 7.38K |
| TradeandOtherPayablesNonCurrent | 0.00 | |||
| NonCurrentDeferredLiabilities | 0.00 | |||
| NonCurrentDeferredTaxesLiabilities | 0.00 | |||
| LongTermDebtAndCapitalLeaseObligation | 487.00 | 66.91K | 150.55K | 7.38K |
| LongTermCapitalLeaseObligation | 487.00 | 66.91K | 150.55K | 7.38K |
| CurrentLiabilities | 1.53M | 730.58K | 998.56K | 971.02K |
| CurrentDebtAndCapitalLeaseObligation | 73.02K | 83.65K | 78.90K | 71.08K |
| CurrentCapitalLeaseObligation | 73.02K | 83.65K | 78.90K | 71.08K |
| PayablesAndAccruedExpenses | 1.46M | 646.93K | 919.66K | 899.94K |
| CurrentAccruedExpenses | 578.73K | 146.27K | 403.06K | 279.26K |
| InterestPayable | 0.00 | |||
| Payables | 880.88K | 500.66K | 516.60K | 620.68K |
| OtherPayable | 189.00K | 189.00K | 400.00K | |
| DuetoRelatedPartiesCurrent | 0.00 | 39.00 | 51.00 | 1.77K |
| AccountsPayable | 880.88K | 311.62K | 327.55K | 218.91K |
| TotalAssets | 3.23M | 5.79M | 8.62M | 26.46M |
| TotalNonCurrentAssets | 1.36M | 154.15K | 233.12K | 8.14M |
| OtherNonCurrentAssets | 5.54K | 5.54K | 5.54K | 5.54K |
| NonCurrentPrepaidAssets | 1.27M | 0.00 | 5.54K | |
| GoodwillAndOtherIntangibleAssets | 0.00 | 0.00 | 8.06M | |
| OtherIntangibleAssets | 8.06M | |||
| NetPPE | 75.69K | 148.61K | 227.59K | 74.18K |
| AccumulatedDepreciation | -29.07K | |||
| GrossPPE | 75.69K | 148.61K | 227.59K | 74.18K |
| OtherProperties | 75.69K | 148.61K | 227.59K | 74.18K |
| MachineryFurnitureEquipment | 29.07K | |||
| CurrentAssets | 1.87M | 5.63M | 8.39M | 18.33M |
| OtherCurrentAssets | 682.29K | 926.30K | 1.88M | 1.76M |
| PrepaidAssets | 1.88M | 1.76M | ||
| Receivables | 0.00 | 70.27K | ||
| DuefromRelatedPartiesCurrent | 0.00 | |||
| TaxesReceivable | 0.00 | 70.27K | ||
| CashCashEquivalentsAndShortTermInvestments | 1.19M | 4.71M | 6.50M | 16.50M |
| CashAndCashEquivalents | 1.19M | 4.71M | 6.50M | 16.50M |
| Line Item | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|
| FreeCashFlow | -11.25M | -8.07M | -9.61M | -8.72M |
| RepurchaseOfCapitalStock | -15.90K | 0.00 | -388.84K | -64.40K |
| RepaymentOfDebt | -5.20K | 0.00 | ||
| IssuanceOfDebt | 0.00 | |||
| IssuanceOfCapitalStock | 7.76M | 6.32M | 0.00 | 10.05M |
| CapitalExpenditure | -3.24K | -2.78K | ||
| InterestPaidSupplementalData | 1.20K | 0.00 | 0.00 | 0.00 |
| IncomeTaxPaidSupplementalData | 0.00 | 0.00 | 0.00 | 0.00 |
| EndCashPosition | 1.19M | 4.71M | 6.50M | 16.50M |
| BeginningCashPosition | 4.71M | 6.50M | 16.50M | 15.42M |
| ChangesInCash | -3.51M | -1.80M | -9.99M | 1.08M |
| FinancingCashFlow | 7.73M | 6.27M | -388.84K | 9.80M |
| CashFlowFromContinuingFinancingActivities | 7.73M | 6.27M | -388.84K | 9.80M |
| NetOtherFinancingCharges | -8.56K | -52.75K | -186.49K | |
| NetCommonStockIssuance | 7.75M | 6.32M | -388.84K | 9.99M |
| CommonStockPayments | -15.90K | 0.00 | -388.84K | -64.40K |
| CommonStockIssuance | 7.76M | 6.32M | 0.00 | 10.05M |
| NetIssuancePaymentsOfDebt | -5.20K | 0.00 | 0.00 | |
| NetShortTermDebtIssuance | 0.00 | |||
| ShortTermDebtIssuance | 0.00 | |||
| NetLongTermDebtIssuance | -5.20K | 0.00 | 0.00 | |
| LongTermDebtPayments | -5.20K | 0.00 | ||
| LongTermDebtIssuance | 0.00 | |||
| InvestingCashFlow | -3.24K | -2.78K | 0.00 | |
| CashFlowFromContinuingInvestingActivities | -3.24K | -2.78K | 0.00 | |
| NetPPEPurchaseAndSale | -3.24K | -2.78K | 0.00 | |
| PurchaseOfPPE | -3.24K | -2.78K | 0.00 | |
| OperatingCashFlow | -11.25M | -8.06M | -9.61M | -8.72M |
| CashFlowFromContinuingOperatingActivities | -11.25M | -8.06M | -9.61M | -8.72M |
| ChangeInWorkingCapital | -112.40K | 605.21K | 543.60K | -1.18M |
| ChangeInOtherWorkingCapital | -12.00 | -1.72K | 86.64K | |
| ChangeInOtherCurrentLiabilities | -83.65K | -78.90K | -87.94K | -87.20K |
| ChangeInPayablesAndAccruedExpense | 1.00M | -272.72K | 352.44K | -166.84K |
| ChangeInAccruedExpense | 432.46K | -256.79K | 243.80K | -65.05K |
| ChangeInInterestPayable | 362.00 | |||
| ChangeInPayable | 569.26K | -15.93K | 108.64K | -101.79K |
| ChangeInAccountPayable | 569.26K | -15.93K | 108.64K | -101.79K |
| ChangeInPrepaidAssets | -1.03M | 956.83K | 210.55K | -1.02M |
| ChangeInReceivables | -39.00 | -12.00 | 70.27K | 6.75K |
| OtherNonCashItems | 87.18K | 1.39M | 390.13K | 384.38K |
| StockBasedCompensation | 629.51K | 1.06M | 8.83M | 3.41M |
| AssetImpairmentCharge | 0.00 | 7.27M | 0.00 | |
| DeferredTax | 0.00 | -530.61K | ||
| DeferredIncomeTax | 0.00 | -530.61K | ||
| DepreciationAmortizationDepletion | 782.00 | 222.00 | 788.50K | 790.97K |
| DepreciationAndAmortization | 782.00 | 222.00 | 788.50K | 790.97K |
| AmortizationCashFlow | 0.00 | 788.50K | 790.49K | |
| AmortizationOfIntangibles | 0.00 | 788.50K | 790.49K | |
| Depreciation | 782.00 | 222.00 | 0.00 | 484.00 |
| OperatingGainsLosses | -163.77K | |||
| NetIncomeFromContinuingOperations | -11.85M | -11.12M | -27.42M | -11.43M |
SEC Filings
Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.
Public Trades for PCSA
| Date | User | Asset | Broker | Type | Position Size | Entry Price | Patterns |
|---|